CHO-H01 at RP2D Clinical Trials

1 actively recruiting trial

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

Cho Pharma Inc.1

Indications

Non-hodgkin Lymphoma1
Cancer1

Other1 trial

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.